Whooping Cough:

Pertussis, literally meaning “a violent cough,” also known as whooping cough or “the cough of 100 days,” was first described in the Paris epidemic of 1578. Bordet Ella pertussis, the causative organism, was discovered in 1906, and a vaccine was developed in the 1940s. Before the pertussis vaccine was developed, pertussis was a major cause of infant morbidity and mortality. This activity describes the presentation and management of pertussis and highlights the role of the interprofessional team in the treatment of affected patients and families.

Objectives:

Identify the etiology of pertussis.
Describe the typical presentation of a patient with pertussis.
Outline the treatment and management options available for pertussis.
Summarize interprofessional team strategies for improving care coordination and communication to enhance the care of patients with pertussis and improve patient outcomes.

Introduction

Pertussis, literally meaning “a violent cough,” also known as whooping cough or “the cough of 100 days,” was first described in the Paris epidemic of 1578. Bordet Ella pertussis, the causative organism, was discovered in 1906, and a vaccine was developed in the 1940s. Before the pertussis vaccine was developed, pertussis was a major cause of infant morbidity and mortality. Pertussis is a serious illness with very high morbidity and mortality.

Etiology

The causative organisms of pertussis are Bordet Ella pertussis and Bordet Ella Para pertussis. Bordet Ella is spread by airborne droplets and is highly contagious. Pertussis often affects 100% of non-immune household contacts. Immunity wanes to 50% 12 years after completing a vaccination series. Immunocompromised persons can also contract Bordet Ella bronchiseptica, which typically affects animals and is commonly known as “a kennel cough.”

Humans are the sole reservoir for Bordet Ella; the organism is spread via aerosolized droplets produced during a cough. The organism is highly contagious, with the majority of cases occurring during summer.

Risk factors for acquiring pertussis include:

Pregnancy
Epidemic exposure
Lack of immunization
Close contact with an infected individual

Epidemiology

Reported pertussis cases are increasing in the United States and worldwide. The prevalence of pertussis in the United States sharply declined from 150,000 to 250,000 cases per year in the revaccination era to 1010 cases reported in 1976. Since then, pertussis has been on the rise, which is partially attributed to waning adolescent and adult immunity. Although pertussis largely remains a pediatric disease, with 38% of cases occurring in infants younger than 6 months and 71% of cases occurring in children younger than 5 years, adolescents and adults can also contract the disease and are likely contributing to the increasing number of both adult and pediatric cases seen over the past three decades. Worldwide, there are over 24 million cases annually, with greater than 160,000 deaths. The Center for Disease Control and Prevention (CDC) reported over 48,000 cases in the United States in 2012, the most recent year for which this data is available. Due to difficulty in diagnosis, the CDC estimates likely underreporting.

Pathophysiology

Bordet Ella is a gram-negative coccobacillus that adheres to ciliated respiratory epithelial cells. Local inflammatory changes occur in the mucosal lining of the respiratory tract. Released toxins (pertussis toxin, dermonecrotic toxin, adenylate cyclase toxin, and tracheal cytotoxic) act locally and systemically, although the organism itself does not fully penetrate the respiratory tract, and almost never is found in blood cultures.

History and Physical

After an incubation period of 1 to 3 weeks, pertussis infection typically progresses through three distinct stages: the catarrhal phase, the paroxysmal phase, and the convalescent phase. The catarrhal phase presents similarly to other upper respiratory tract infections, with fever, fatigue, rhinorrhea, and conjunctival injection. The catarrhal phase lasts 1 to 2 weeks and is the most infectious stage of the disease.

The paroxysmal phase follows the catarrhal phase and is characterized by paroxysms of a staccato cough and the resolution of fever. The patient typically coughs repeatedly, followed by forceful inspiration, which creates the characteristic “whoop.” These episodes may be triggered by cold or noise and are more common at night. Patients are nontoxic-appearing in between paroxysms, but during coughing episodes, may exhibit cyanosis, diaphoresis, or apnea. Immediately following a paroxysm, patients may develop post-jussive emesis, syncope, or apnea.

Finally, during the convalescent phase, a residual cough persists for weeks to months, usually triggered by exposure to another upper respiratory infection or irritant. Atypical presentations are common in infants, and fever may not occur. Rather, tachypnea, apnea, cyanosis, and episodic bradycardia may be the presenting features. Increased intrathoracic pressure from coughing may result in petechial above the nipple line, sub conjunctival hemorrhage, and epistaxis. Breath sounds are variable; auscultation may reveal clear lungs or rhonchi, while rales suggest superimposed pneumonia. The inspiratory whoop or gasp is usually heard in children between 6 months to 5 years.

Evaluation

Testing for pertussis is not readily available in the emergency department. Nasopharyngeal culture and polymerase chain reaction (PCR) may yield laboratory confirmation, but the fastidious and slow-growing Bordet Ella organisms require specialized media, and cultures are typically not positive for 3 to 7 days. In adults, by the time the diagnosis is suspected, cultures are typically negative (96%), and overall culture sensitivity is only 20% to 40%. PCR is more sensitive and specific than culture, but testing is not widely available.

In the emergency department, pertussis should be considered in patients with prolonged cough, especially occurring in paroxysms or with whoops or post-jussive emesis. During the late catarrhal and early paroxysmal phases, leukocytosis (often 25,000 to 60,000 per mL) with lymphocytosis may raise suspicion for pertussis. In a study of 100 infants less than 120 days old and admitted to a pediatric intensive care unit, there was a significantly higher leukocytosis in the five fatal cases. Unfortunately, leukocytosis may be the only laboratory finding useful in the emergency department. Chest x-ray findings are nonspecific and may show per bronchial thickening, atelectasis, or infiltrates. The classic association, though not often seen, is a “shaggy” right heart border.

Treatment / Management

Treatment of pertussis is largely supportive, including oxygen, suctioning, hydration, and avoidance of respiratory irritants. Parenteral nutrition may be necessary as the disease tends to have a prolonged course. Hospitalization is indicated for patients with superimposed pneumonia, hypoxia, central nervous system (CNS) complications, or who are unable to tolerate nutrition and hydration by mouth. Patients less than 1-year-old are not fully vaccinated and carry the greatest risk of morbidity and mortality; they should be hospitalized regardless of symptoms. Neonates should be admitted to an intensive care setting as life-threatening cardiopulmonary complications and arrest can occur unexpectedly.

Antibiotic effect on the duration or severity of the disease is minimal when started in the catarrhal phase and not proven effective when started in the paroxysmal phase. Rather, the primary goal of antibiotic treatment is to decrease the carriage and spread of disease. Erythromycin (40 to 50 mg/kg per day, maximum 2 g per day, in 2 to 3 divided doses) is the first-line treatment for pertussis. Azithromycin (10 mg/kg per day on day 1 followed by 5 mg/kg on days 2 to 5) and clarithromycin (15 mg/kg per day in two divided doses) are alternative treatments. Trimethoprim-sulfamethoxazole (8 mg/kg per day of trimethoprim) has been used as an alternative in macrolide-allergic patients, but its efficacy has not been proven. The macrolides are not recommended for infants less than 4 weeks old for fear that this may lead to infantile hypertrophic pyloric stenosis.

Strict isolation is important while the patient remains infectious. Pertussis is contagious throughout the catarrhal phase and for 3 weeks after the onset of the paroxysmal phase. In patients treated with antibiotics, isolation should be continued for at least 5 days after treatment is initiated. Postexposure prophylaxis with erythromycin is recommended for all household contacts.

Corticosteroids have not shown definite benefit in reducing the severity and course of illness but are sometimes given to critically ill infants. Beta2-agonists, pertussis immune globulin, cough suppressants, and antihistamines are not effective. Exchange blood transfusion therapy for leukocytosis with lymphocytosis may be considered. Close contacts should be treated with azithromycin or erythromycin.

Vaccination is recommended with the acellular vaccine at ages 2,4,6, 15-18 months, and at ages 4 to 6 years. In addition, the CDC recommends a single dose of Tdap for all adults to reduce transmission to children. Adverse effects of the vaccine include crying and febrile seizures, but severe neurological effects are rare. The vaccine can also be administered during the third trimester to pregnant women without causing harm to the fetus. DTaP is approved during the last 3 months of pregnancy to prevent pertussis in infants under 2 months old.

Differential Diagnosis

Pertussis initially presents similarly to other respiratory infections, such as viral upper respiratory infection, bronchiolitis, pneumonia, and tuberculosis. Key differentiating factors of pertussis include typical progression through the three phases and persistent cough without fever. Foreign body aspiration should be considered in younger patients, and exacerbation of chronic obstructive pulmonary disease should be considered in older patients with the appropriate history. The striking leukocytosis may also be confused with leukemia.

Prognosis

Most people infected with pertussis will fully recover, albeit usually after a prolonged illness of months. Infants and older adults tend to have the highest mortality and morbidity, respectively. The infant death rate is about 2% of cases and accounts for 96% of deaths related to pertussis. Older adults tend to have increased morbidity due to other chronic medical conditions, as well as an increased rate of complications, such as pneumonia. Secondary complications like pneumonia, seizures, and encephalopathy may occur in some patients.

Complications

Secondary pneumonia or otitis media may occur. Superimposed pneumonia is a major cause of mortality in infants and young children and may be caused by aspiration of gastric contents during paroxysms of cough or because of decreased respiratory clearance of pathogens. Fever should subside during the catarrhal phase, and its presence during the paroxysmal phase should raise suspicion for pneumonia. The most common causes of secondary bacterial pneumonia are Streptococcus pneumonia, Streptococcus pyogenic, Homophiles influenza, and Staphylococcus aureus; although viral infections with the respiratory syncytial virus, cytomegalovirus, and adenovirus superinfections are also common.

Rarely (less than 2% of cases), CNS complications such as seizures and encephalopathy can occur, likely secondary to hypoxia, hypoglycemia, toxins, secondary infections, or cerebral bleeding from increased pressure during coughing. Sudden increases in intrathoracic and intraabdominal pressures can also result in periorbital edema, pneumothorax, pneumomediastinum, subcutaneous emphysema, diaphragmatic rupture, umbilical and inguinal hernias, and rectal prolapse. Pertussis toxin also causes histamine hypersensitivity and increased insulin secretion.

Infants are particularly prone to bradycardia, hypotension, and cardiac arrest from pertussis. The development of pulmonary hypertension has been increasingly recognized as a factor contributing to infantile mortality, as it may lead to worsening systemic hypotension and hypoxia.

Deterrence and Patient Education

Pertussis vaccine exists in both whole-cell (DPT) and acellular (DTaP) forms. In 1991, the acellular formulation largely replaced the whole-cell vaccine, which had been associated with acute encephalopathy and prolonged seizures. The acellular form has fewer adverse effects and is as effective as the whole-cell formulation. As a result, the whole-cell preparation is only recommended when the acellular form is not available. Common adverse effects are mild and include fever, irritability, behavioral changes, and pain at the injection site. Less commonly, moderately severe reactions, including fever over 40 C, persistent and high-pitched crying, and seizures may occur. A recent study of over 50,000 patients vaccinated from 1981 to 2016 did not detect any new or unexpected adverse effects.

Pearls and Other Issues

Laboratory and radiographic confirmation of pertussis is a challenge in the emergency department setting. It is important to maintain a low threshold of suspicion for pertussis in any patient presenting with prolonged cough, regardless of immunization status. A complete blood count with attention to leukocytosis and lymphocytosis may be the best diagnostic screening tool in the emergency department.

Enhancing Healthcare Team Outcomes

The management of pertussis is best done with an interprofessional team that includes the pharmacist and nurses. With a strong anti-vaccine movement, patient education is key. Parents and caregivers have to be informed that the adverse effects of the vaccine are rare. In an era of anti-vaccination sentiments, clinicians should educate the public that the vaccine is safe and effective.

Pertussis immunity wanes significantly about seven years after vaccination and about 15 years after natural infection. As a result, the CDC Advisory Committee on Immunization Practices recommends routine booster immunization, starting at ages 11 to 18 years. A study of almost 70,000 patients showed no significant adverse effects for patients receiving Tdap instead of Td as a tetanus booster; in patients requiring a tetanus booster in the emergency department, adding the acellular pertussis component could be considered, especially in pregnant women. Mothers are often identified as the source of pertussis infection in newborns who have not completed their vaccination series, and preliminary data suggest that infants of mothers vaccinated against both influenza and pertussis may be at lower risk for contracting pertussis.

Pertussis is a reportable infection in the US, and even one case must be reported immediately, and control measures to prevent transmission should be in place. Open communication between the interprofessional team is vital to ensure that patients are treated with optimal care and that vaccination protocols are in place.

Whooping Cough Vaccine

Whooping cough (pertussis) is a respiratory infection that’s caused by the Bordet Ella pertussis bacteria. It spreads easily through coughing or sneezing. The infection often triggers severe coughing episodes that make it difficult to eat, breathe, or sleep. While it is often thought of as a childhood disease, adults also develop the infection. Fortunately, there are vaccines available to protect against whooping cough. This article discusses who needs a vaccine, age ranges, and possible side effects.

Do I Need the Whooping Cough Vaccine?

In the United States, vaccination against whooping cough is recommended for people of all age groups. This include babies, children, teens, adults, and pregnant people.

The Centers for Disease Control and Prevention (CDC) recommends two vaccines to protect against whooping cough:

Diphtheria, tetanus, and pertussis (DTaP) for babies and children under age 7
Tetanus, diphtheria, and pertussis (Tdap) for older children and adults

Information for Babies and Toddlers

Whooping cough can be particularly dangerous for babies. It can lead to complications like convulsions, pneumonia, brain damage, and even death.

Babies and toddlers should receive the DTaP vaccines as part of their routine vaccination schedule.

Information for Preteens and Teens

Preteens and teens will need one booster shot of the Tdap vaccine as part of their routine vaccination schedule. Ask your child’s healthcare provider if you think they’ve missed this shot.

Information for Adults

Adults who miss the Tdap dose as a teen will need a Tdap shot to protect against whooping cough. This should be followed by a booster shot every 10 years.

It's particularly important that adults who are at high-risk for complications are vaccinated. This includes people with asthma. Only about 31% of adults in the United States report receiving their pertussis vaccine in the past 10 years.

Information for Pregnant People

Pregnant people should receive one booster shot of the Tdap vaccine during each pregnancy to protect both parent and baby.

Other Ways to Prevent Whooping Cough

Vaccination is the best way to lower your chances of getting whooping cough. It's also important to wash your hands often, cover your mouth when you cough, and stay home when you're not feeling well to prevent transmission.

At What Age Should I Get the Whooping Cough Vaccine?

When you initially get the vaccine and how often you get it after that will depend on your age:³

Centers for Disease Control and Prevention. Diphtheria, tetanus, and whooping cough vaccination: what everyone should know.

Preteens and teens: Preteens and teens should receive their Tdap booster shot at age 11 or 12.
Adults: Adults who were not vaccinated as teens can receive their Tdap at any time.
Pregnant people: The CDC recommends that pregnant people receive their Tdap vaccine between weeks 27-36 of each pregnancy.

Information Regarding Babies and Toddlers

Babies and toddlers will need a DTaP vaccine dose at the following ages:

2 months
4 months
6 months
15 through 18 months
4 through 6 years

Who Shouldn’t Get the Whooping Cough Vaccine?

You should not receive a pertussis vaccine if you’re allergic to any ingredient in the vaccine or have had a serious reaction to diphtheria, tetanus, or whooping cough vaccines in the past.

Before you receive your whooping cough vaccine, let your healthcare provider know if you:

Have had a previous reaction to vaccines
Have seizures or other nervous system problems

If you’re not feeling well, it might be a good idea to wait until you're better to get your vaccine.